Treatments

DISEASE PROGRESSION IN PATIENTS WITH CYSTIC FIBROSIS TREATED WITH IVACAFTOR: DATA FROM NATIONAL US AND UK REGISTRIES

Authors: Nataliya Volkovaa, Kristin Moya, Jennifer Evansb, Daniel Campbella, Simon Tiana, Christopher Simarda, Mark Higginsc, Michael W. Konstand, Gregory S. Sawickie, Alexander Elbertf, Susan C. Charmang, Bruce C. Marshallf, Diana […]

 Read more

THE USE OF ANTIMICROBIAL SUSCEPTIBILITY TESTING IN PEDIATRIC CYSTIC FIBROSIS PULMONARY EXACERBATIONS

Authors: Jonathan D. Cogen1, Kathryn B. Whitlock2, Ronald L. Gibson1, Lucas R. Hoffman1, Donald R. VanDevanter3 Affiliations: 1Division of Pulmonary & Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, […]

 Read more

THE EFFECTS OF CYCLED INHALED AZTREONAM ON THE CYSTIC FIBROSIS (CF) LUNG MICROBIOME

Authors: Alya A. Heirali1; Nicole Acosta1; Douglas G. Storey1,2; Matthew L. Workentine3; Ranjani Somayaji1,4; Isabelle Laforest-Lapointe5,6, Winnie Leung7; Bradley S. Quon8; Yves Berthiaum9; Harvey R. Rabin1,4; Barbara J. Waddell1, Laura […]

 Read more

PHYSICAL ACTIVITY AND ASSOCIATIONS WITH CLINICAL OUTCOME MEASURES IN ADULTS WITH CYSTIC FIBROSIS, A SYSTEMATIC REVIEW

Authors: James Shelley1, Lynne M Boddy1, Zoe R Knowles1, Claire E Stewart1, & Ellen A Dawson1. Affiliations: 1Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, L3 […]

 Read more

SHORT-TERM AND LONG-TERM RESPONSE TO PULMONARY EXACERBATION TREATMENT IN CYSTIC FIBROSIS

Authors: Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA   What was your research question? We looked at differences in pulmonary exacerbation care in […]

 Read more

INVESTIGATING THE EFFECTS OF LONG-TERM DORNASE ALFA USE ON LUNG FUNCTION USING REGISTRY DATA

Authors: Newsome SJ1, Daniel RM2, Carr SB3, Bilton D4 and Keogh RH1 Affiliations: 1Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK 2Division of Population Medicine, […]

 Read more

NON-INVASIVE VENTILATION AND CLINICAL OUTCOMES IN CYSTIC FIBROSIS: FINDINGS FROM THE UK CF REGISTRY

Authors: Olga Archangelidi1, Siobhán B. Carr2, Nicholas J. Simmonds1,2, Diana Bilton1,2, Winston Banya1,2, Paul Cullinan1 on behalf of CF-EpiNet Affiliations: 1National Heart and Lung Institute, Imperial College London, 2Royal Brompton […]

 Read more

REPEATED HOT WATER AND STEAM DISINFECTION OF PARI LC PLUS NEBULIZERS ALTERS NEBULIZER OUTPUT

Authors: Melanie Sue Collins, MD1,2, Matthew O’Brien3, Craig M. Schramm1,2, MD, Thomas S Murray MD/PhD3,4 Affiliations: 1Pediatric Pulmonary Medicine, Connecticut Children’s Medical Center, Hartford, CT 2Pediatrics, University of Connecticut School […]

 Read more

USE OF TELAVANCIN IN ADOLESCENT PATIENTS WITH CYSTIC FIBROSIS AND PRIOR INTOLERANCE TO VANCOMYCIN: A CASE SERIES

Authors: Adam T. Bernsteina, Margaret W. Leighb, Jennifer L. Goralskib,c, Charles R. Esther Jrb, Cameron J. McKinziea  Affiliations: aDepartment of Pharmacy, University of North Carolina Medical Center, 101 Manning Drive, […]

 Read more

COMBINED ANTIFUNGAL THERAPY IS SUPERIOR TO MONOTHERAPY IN PULMONARY SCEDOSPORIOSIS IN CYSTIC FIBROSIS

Authors: Carsten Schwarz1, Claudia Brandt1, Volker Melicha², Christoph Runge3, Eberhard Heuer3, Hany Sahly4, Martin Schebek5, Holger Köster6, Jean-Philippe Bouchara7, Thomas Biedermann8, Peter Meißner9, Jörg Große-Onnebrink10, Heino Skopnik11, Dominik Hartl12, Ludwig […]

 Read more

THE GEOGRAPHIC IMPACT ON HOSPITALIZATION IN PATIENTS WITH CYSTIC FIBROSIS

Authors: Kopp BT, Nicholson L, Paul G, Tobias J, Ramanathan C, Hayes D Jr   What was your research question? We looked at whether geographic location influences hospitalizations for pulmonary […]

 Read more

EFFECT OF TREATMENT OF CYSTIC FIBROSIS PULMONARY EXACERBATIONS ON SYSTEMIC INFLAMMATION

Authors: Sagel SD, Thompson V, Chmiel JF, Montgomery GS, Nasr SZ, Perkett E, Saavedra MT, Slovis B, Anthony MM, Emmett P, Heltshe SL   What was your research question? We […]

 Read more

Contact information

Subscribe to newsletter